Compare Ginkgo Bioworks Holdings Inc (DNA) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Micron Technology, Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Micron Technology, Inc. trades at $977.92 (market cap $1.11T). The key difference: Micron Technology, Inc. is far larger — about 1879.7× Ginkgo Bioworks Holdings Inc's market cap, and Micron Technology, Inc. pays a 0.05% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | MU | |
|---|---|---|
Market Cap | $590.53M | $1.11T |
Sector | Health | Technology |
52-Week High | $16.14 | $1.21K |
52-Week Low | $5.48 | $104.88 |
Enterprise Value | $627.78M | $1.09T |
Dividend Yield | — | 0.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Micron Technology (MU) trades at $937.00, down 4.32% today, but maintains strong bullish technical momentum with support near $924. The company demonstrates robust fundamentals, with Q1 2026 EPS beating estimates at $25.11 versus $20.98 expected, and revenue growth accelerating to $37.38 billion in 2025. Analyst sentiment remains overwhelmingly positive, with 81% recommending Buy and a consensus price target of $1,550.
Outlook is favorable driven by AI memory demand and pricing power, though risks include competitive pressure from SK Hynix and cyclical semiconductor volatility. Cash flow trends show strengthening operational performance, with net cash flow turning positive at $2.59 billion in 2025, supporting future growth investments and shareholder returns via dividends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
